203 related articles for article (PubMed ID: 31994421)
1. Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases.
Jackson K; Bahna SL
Expert Rev Clin Immunol; 2020 Mar; 16(3):311-319. PubMed ID: 31994421
[No Abstract] [Full Text] [Related]
2. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database.
Cutroneo PM; Arzenton E; Furci F; Scapini F; Bulzomì M; Luxi N; Caminati M; Senna G; Moretti U; Trifirò G
BioDrugs; 2024 May; 38(3):425-448. PubMed ID: 38489062
[TBL] [Abstract][Full Text] [Related]
3. Smaller Differences in the Comparative Effectiveness of Biologics in Reducing Asthma-Related Hospitalizations Compared With Overall Exacerbations.
Akenroye A; Marshall J; Simon AL; Hague C; Costa R; Jamal-Allial A; McMahill-Walraven CN; Haffenreffer K; Han A; Wu AC
J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1568-1574.e2. PubMed ID: 38431251
[TBL] [Abstract][Full Text] [Related]
4. Comparative Impact of Asthma Biologics: A Nationwide US Claim-Based Analysis.
Al-Shaikhly T; Norris MR; Dennis EH; Liu G; Craig TJ
J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1558-1567. PubMed ID: 38423294
[TBL] [Abstract][Full Text] [Related]
5. [Adverse events in biologics for severe asthma].
Dargentolle G; Georges M; Beltramo G; Poisson C; Bonniaud P
Rev Mal Respir; 2024 May; 41(5):372-381. PubMed ID: 38653607
[TBL] [Abstract][Full Text] [Related]
6. Advancements in biologic therapy in eosinophilic asthma.
Patadia R; Casale TB; Fowler J; Patel S; Cardet JC
Expert Opin Biol Ther; 2024 Apr; 24(4):251-261. PubMed ID: 38619468
[TBL] [Abstract][Full Text] [Related]
7. Biological treatments in childhood asthma.
Nieto-García A; Nieto-Cid M; Mazón-Ramos Á
Curr Opin Allergy Clin Immunol; 2024 Jun; 24(3):114-121. PubMed ID: 38567842
[TBL] [Abstract][Full Text] [Related]
8. Omalizumab. A review of the new treatment of allergic asthma and seasonal allergic rhinitis.
Félix Toledo R; Negro Alvarez JM; Miralles López JC
Allergol Immunopathol (Madr); 2002; 30(2):94-9. PubMed ID: 11958741
[TBL] [Abstract][Full Text] [Related]
9. Incidence of Anti-Drug Antibodies to Monoclonal Antibodies in Asthma: A Systematic Review and Meta-Analysis.
Chen ML; Nopsopon T; Akenroye A
J Allergy Clin Immunol Pract; 2023 May; 11(5):1475-1484.e20. PubMed ID: 36716995
[TBL] [Abstract][Full Text] [Related]
10. Long-term multicenter comparison shows equivalent efficacy of monoclonal antibodies in severe asthma therapy.
Kayser MZ; Suhling H; Fuge J; Hinze CA; Drick N; Kneidinger N; Behr J; Taube C; Welte T; Haasler I; Milger K
BMC Pulm Med; 2024 Mar; 24(1):149. PubMed ID: 38515071
[TBL] [Abstract][Full Text] [Related]
11. Characterizing Adverse Events of Biologic Treatment of T2 Disease: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
Stack TJ; Kim S; Lamb MM; Mohammad I; Zeatoun A; Lopez E; Klatt-Cromwell C; Thorp BD; Ebert CS; Senior BA; Kimple AJ; Alicea D
ORL J Otorhinolaryngol Relat Spec; 2023; 85(6):329-339. PubMed ID: 37963438
[TBL] [Abstract][Full Text] [Related]
12. Anaphylaxis to three humanized antibodies for severe asthma: a case study.
Jingo K; Harada N; Nishioki T; Torasawa M; Yamada T; Asao T; Takagi H; Takeshige T; Ito J; Takahashi K
Allergy Asthma Clin Immunol; 2020; 16():46. PubMed ID: 32536947
[TBL] [Abstract][Full Text] [Related]
13. Navigating biologic therapies in elderly asthma.
Ji H; Tan LD; Hafzalla GW; Nguyen N; Alismail A
Respir Med; 2024 Jun; 227():107655. PubMed ID: 38679338
[TBL] [Abstract][Full Text] [Related]
14. Mapping knowledge structure and research of the biologic treatment of asthma: A bibliometric study.
Sun J; Bai S; Zhao J; Li D; Ma X; Ma L; Su X
Front Immunol; 2023; 14():1034755. PubMed ID: 36845128
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 in a patient with severe asthma using mepolizumab.
Aksu K; Yesilkaya S; Topel M; Turkyilmaz S; Ercelebi DC; Oncul A; Kalkan IK; Ates H
Allergy Asthma Proc; 2021 Mar; 42(2):e55-e57. PubMed ID: 33536114
[No Abstract] [Full Text] [Related]
16. Long-term safety, durability of response, cessation and switching of biologics.
Mohan A; Qiu AY; Lugogo N
Curr Opin Pulm Med; 2024 May; 30(3):303-312. PubMed ID: 38426355
[TBL] [Abstract][Full Text] [Related]
17. Combination Anti-IgE and Anti-IL5 Therapy in a Pediatric Patient With Severe Persistent Asthma.
Fox HM; Rotolo SM
J Pediatr Pharmacol Ther; 2021; 26(3):306-310. PubMed ID: 33833634
[TBL] [Abstract][Full Text] [Related]
18. [Application of biologicals in patients with food allergies].
Agar Muñoz AM; Galván Calle CA
Rev Alerg Mex; 2023 Dec; 70(4):297-299. PubMed ID: 38506875
[TBL] [Abstract][Full Text] [Related]
19. Incidence of adverse events prompting switching between biologics among adults with asthma: A retrospective cohort study.
Akenroye A; Zhou G; Jackson JW; Segal J; Alexander GC; Singh S
Allergy; 2023 Apr; 78(4):1116-1119. PubMed ID: 36286487
[No Abstract] [Full Text] [Related]
20. Pharmacoequity and Biologics in the Allergy Clinic: Providing the Right Care, at the Right Time, Every Time, to Everyone.
Conway AE; Lieberman J; Codispoti CD; Mahdavinia M; Anagnostou A; Hsu Blatman KS; Lang DM; Oppenheimer J; Mosnaim GS; Bukstein D; Shaker M
J Allergy Clin Immunol Pract; 2024 May; 12(5):1170-1180. PubMed ID: 38458435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
